If you have been reading about GHRH receptor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-10-27. Numbers and descriptions here follow the published literature rather than marketing material.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
| Property | Value | Notes |
|---|---|---|
| Primary target | Growth hormone-releasing hormone receptor | Located on anterior pituitary somatotroph cells. |
| Receptor class | G protein-coupled receptor | Activation increases intracellular cyclic AMP. |
| Main downstream hormone | Growth hormone and insulin-like growth factor 1 | Growth hormone release precedes IGF-1 elevation. |
| Primary studied effect | Reduction in visceral adipose tissue | Measured by computed tomography in clinical trials. |
| Approximate half-life | 26–38 minutes after subcutaneous administration | Values vary by assay and study population. |
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Once reconstituted, the peptide is handled as a solution and is less stable than the lyophilized powder. Aqueous solutions are commonly kept cold and used within a defined period. Buffer composition and pH influence degradation rates, with extremes of acidity or alkalinity accelerating hydrolysis. Preservatives may be added in multi-dose formats to limit microbial growth. Freezing and thawing of solutions is generally avoided because it can cause precipitation or loss of activity.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass and detects chemical modifications. Peptide mapping and amino acid analysis can verify sequence integrity. Water content is measured by Karl Fischer titration, and residual solvents may be checked by gas chromatography. These methods together support batch-to-batch consistency and routine quality control.
Lyophilized tesamorelin is generally stored refrigerated at temperatures between 2 and 8 degrees Celsius. The solid form is comparatively stable when kept dry and protected from light. Moisture uptake can promote aggregation and degradation, so sealed containers with desiccant are common. Researchers typically avoid repeated temperature cycling, which may stress the peptide. Documentation accompanying reference materials usually specifies a shelf life under these conditions.
Research supply is often accompanied by a certificate of analysis listing chromatographic purity, mass confirmation, and storage conditions. Laboratories compare that document with an independent test when material is intended for bench work, since certificates describe a batch rather than an individual vial. Published studies usually state the source and purity of the peptide because small differences in purity can shift measured activity. Full analytical validation is rarely reported, which leaves batch-to-batch comparability an open question.
The peptide is supplied as a lyophilized powder in single-use vials and is normally kept refrigerated between two and eight degrees Celsius, protected from light. Once dissolved, the solution is handled carefully because peptide bonds and the acyl modification can degrade under warm or alkaline conditions. Vials are inspected for cracks, and the powder is checked for color and uniformity before handling. Temperature excursions during shipping are a frequent reason for quality questions.
Identity and purity are assessed with reversed-phase high-performance liquid chromatography, which separates the peptide from truncated or oxidized forms. Mass spectrometry confirms the expected molecular weight, and peptide mapping after enzymatic digestion verifies the amino acid sequence. Water content is measured because residual moisture affects stability, and tests for aggregates or particulates are standard for injectable peptides. Circular dichroism can indicate whether the molecule has adopted an unexpected secondary structure in solution.
Identity and purity are judged through a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact peptide from truncated, oxidized, and deamidated variants, and the resulting peak-area percentages yield a purity figure. Electrospray ionization mass spectrometry confirms the expected molecular mass and can expose unanticipated modifications. Amino acid analysis and peptide mapping support sequence fidelity, while water content, pH, sterility, and bacterial endotoxin testing describe the physical and microbiological attributes of a finished lot.
Regulatory position depends on jurisdiction and on the form in which the material is sold. A branded product holds approval in the United States for a defined indication, and prescribing is confined to that label. Material marketed for laboratory research is not evaluated for human use and carries no such clearance. Independent verification therefore rests on certificates of analysis, third-party testing, and documented chain of custody. The substance also appears on the World Anti-Doping Agency prohibited list within the category covering growth hormone-releasing factors.
=== Metabolic effects === As a major growth factor, IGF1 is responsible for stimulating growth of all cell types, and causing significant metabolic effects. One important metabolic effect of IGF1 is signaling cells that sufficient nutrients are available for them to undergo hypertrophy and cell division. Its effects also include inhibiting cell apoptosis and increasing the production of cellular proteins. IGF1 receptors are ubiquitous, which allows for metabolic changes caused by IGF1 to occur in all cell types. IGF1's metabolic effects are far-reaching and can coordinate protein, carbohydrate, and fat metabolism in a variety of different cell types. The regulation of IGF1's metabolic effects on target tissues is also coordinated with other hormones such as growth hormone and insulin.
=== Routes for topical drug administration === In general, there are three possible routes for drug administration into or across the skin. The first one is the transcellular route, where the drugs are required to pass through both lipid matrix and dead corneocytes of the stratum corneum. The second one is the intercellular route, where the drugs only have to pass through lipid domains between corneocytes. The third one is the trans-appendageal route, where the drugs are transported by hair follicles, sebaceous glands, or sweat glands. The most common route for drug delivery into the skin is the intercellular route. Multiple steps are involved.
=== Alzheimer's disease === In November 2025, Novo Nordisk announced top-line results from two large-scale studies, evoke and evoke+. The studies reported failure to slow the progression of Alzheimer's disease versus placebo.
Cremasco, V., Woodruff, M. C., Onder, L., Cupovic, J., Nieves-Bonilla, J. M., Schildberg, F. A., Chang, J., Harvey, C. J., Wucherpfennig, B., Ludewig, B., Carroll, M. C., & Turley, S. J. (2014). B cell homeostasis and follicle confines are governed by fibroblastic reticular cells. Nature Immunology, 15(8), 973–981. https://doi.org/10.1038/ni.2965 Li, L., Lu, Y., Zhou, L., Shi, S., Zhu, X., & Zhang, L. (2021). Lymph node fibroblastic reticular cells steer immune responses. Trends in Immunology. https://doi.org/10.1016/j.it.2021.06.002 Link, A., Vogt, T. K., Favre, S., Britschgi, M. R., Acha-Orbea, H., Hinz, B., Cyster, J. G., & Luther, S. A. (2007). Fibroblastic reticular cells in lymph nodes regulate the homeostasis of naïve T cells. Nature Immunology, 8(11), 1255–1265. https://doi.org/10.1038/ni1513 Lütge, M., Pikor, N. B., & Ludewig, B. (2021). Differentiation and activation of fibroblastic reticular cells. Immunological Reviews, 302(1), 32–46. https://doi.org/10.1111/imr.12981 Mueller, S. N., & Germain, R. N. (2015). Stromal cell contributions to the homeostasis and functionality of the immune system. Nature Reviews Immunology, 15(12), 729–740. https://doi.org/10.1038/nri3846 Onder, L., Papadopoulou, C., Lütge, A., Cheng, H.-W., Lütge, M., Perez-Shibayama, C., Gil-Cruz, C., De Martin, A., Kurz, L., Cadosch, N., Pikor, N. B., Rodriguez, R., Born, D., Jochum, W., Leskow, P., Dutly, A., Robinson, M. D., & Ludewig, B. (2025). Fibroblastic reticular cells generate protective intratumoral T cell environments in lung cancer. Cell, 188(2), 430–446.
Sources: en.wikipedia.org
Indium is a chemical element; its symbol is In and its atomic number is 49. It is a silvery-white post-transition metal and one of the softest elements. Chemically, indium is similar to gallium and thallium, and its properties are largely intermediate between the two. It was discovered in 1863 by Ferdinand Reich and Hieronymous Theodor Richter by spectroscopic methods and named for the indigo blue line in its spectrum. Indium is used primarily in the production of flat-panel displays as indium tin oxide (ITO), a transparent and conductive coating applied to glass. It is also used in the semiconductor industry, in low-melting-point metal alloys such as solders and soft-metal high-vacuum seals. It is used in the manufacture of blue and white LED circuits, mainly to produce Indium gallium nitride p-type semiconductor substrates. It is produced exclusively as a by-product during the processing of the ores of other metals, chiefly from sphalerite and other zinc sulfide ores. Indium has no biological role and its compounds are toxic when inhaled or injected into the bloodstream, although they are poorly absorbed following ingestion. Indium has no metabolic role in any organism that has been studied.
=== Finance === According to Nicolas Firzli, director of the World Pensions & Investments Forum, it may be too early to see the emergence of highly innovative AI-informed financial products and services. He argues that "the deployment of AI tools will simply further automatise things: destroying tens of thousands of jobs in banking, financial planning, and pension advice in the process, but I'm not sure it will unleash a new wave of [e.g., sophisticated] pension innovation."
==== Carnivoran research ==== Evidence of impact of competition on diversification of North American and Eurasian carnivorans throughout the last 45 million years is presented by Porto & Quental (2026). A study on the mandibles of extant and extinct carnivorans, providing evidence of overall decoupling of evolution of mandible shape and function, but also possible evidence of modular dynamics in the evolution of mandible, with differences in the pace and correlation of evolution of different anatomical regions, is published by Sansalone et al. (2026). Bartolini-Lucenti et al. (2026) document new occurrences of carnivorans in the Pliocene strata from the Jradzor locality (Armenia), including Baranogale helbingi, Chasmaporthetes lunensis, Pliocrocuta perrieri and cf. Lynx sp., expanding known geographic and temporal ranges of the studied carnivorans. Orcutt et al. (2026) report the discovery of new carnivoran fossil material from the John Day Formation (Oregon, United States), including the first definitive records of Osbornodon sp. and Otarocyon sp. from the studied formation, as well as a possible fossil material of a large amphicyonine. Espinasa et al. (2026) study the composition of the Rancholabrean carnivoran assemblage from the Calera cave system (San Luis Potosí, Mexico), including a growth sequence of Smilodon fatalis. Díaz de León-Muñoz, Siliceo & Ferreira (2026) study the feeding behavior of Magericyon anceps, reporting evidence of resistance of its mandible to loads during hunting, but also evidence of an unexpectedly weak bite.
Sources: en.wikipedia.org
=== Mouse-human hybrid === A mouse-human hybrid is a genetically modified mouse whose genome has both mouse and human genes, thus being a murine form of a human-animal hybrid. For example, genetically modified mice may be born with human leukocyte antigen genes in order to provide a more realistic environment when introducing human white blood cells into them in order to study immune system responses. One such application is the identification of hepatitis C virus (HCV) peptides that bind to HLA, and that can be recognized by the human immune system, thereby potentially being targets for future vaccines against HCV.
=== Glutathione's impact on cellular balance, diseases, and drug development === Townsend's research has focused on the multifaceted role of glutathione and glutathione S-transferase (GST) in human disease, particularly their involvement in anti-cancer drug resistance, protein S-glutathionylation, and redox stress. She explored GSH's role in maintaining cellular balance, serving as a co-factor for enzymes, and influencing posttranslational modifications. This work emphasized GSH's crucial role in combating reactive oxygen species (ROS), implicated in diseases such as cancer, neurodegenerative diseases, cystic fibrosis (CF), HIV, and aging. Collaborating with Tew, she investigated the role of GSTs in the development of resistance to chemotherapy agents, proposing them as inhibitors of the MAP kinase pathway and potential therapeutic targets for various diseases, including neurodegenerative diseases, multiple sclerosis, and asthma. Her studies identified a role for GSTs as enzymatic mediators of S-glutathionylation of proteins. In her further research on cancer chemotherapy, she explored how cisplatin selectively kills proximal tubule cells, identified its metabolic pathway to a nephrotoxin, and showed that the metabolism in these cells is crucial for cisplatin-induced kidney damage, suggesting new targets for inhibition.
The 3C-like protease (3CLpro) or main protease (Mpro), formally known as C30 endopeptidase, is the main protease found in coronaviruses. It cleaves the coronavirus polyprotein at eleven conserved sites. It is a cysteine protease and a member of the PA clan of proteases. It has a cysteine-histidine catalytic dyad at its active site and cleaves a Gln–(Ser/Ala/Gly) peptide bond. The Enzyme Commission refers to this family as SARS coronavirus main proteinase (Mpro; EC 3.4.22.69). The 3CL protease corresponds to coronavirus nonstructural protein 5 (nsp5). The "3C" in the common name refers to the 3C protease (3Cpro) which is a homologous protease found in picornaviruses.
== 10 Point Capital and 600 Restaurant Goal == Slim Chickens in 2019 announced a minority investment by 10 Point Capital. CEO Tom Gordon said the investment would help the company toward its stated goal of opening 600 locations in the next 10 years.
Sources: en.wikipedia.org
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Binding stimulates cyclic AMP signaling and growth hormone secretion. This is the same receptor used by endogenous GHRH.
It does not act directly on adipose tissue as a primary mechanism. Instead, it increases endogenous growth hormone, which then influences lipolysis and fat distribution. The reduction in visceral fat is an indirect pharmacodynamic effect.
Tesamorelin acts upstream at the pituitary to amplify natural pulsatile growth hormone release. Growth hormone injections provide exogenous hormone and bypass pituitary regulation. The two approaches therefore differ in feedback control and hormonal dynamics.
It mimics a natural hypothalamic signal that tells the pituitary to release growth hormone. The result is a rise in circulating growth hormone and, indirectly, in insulin-like growth factor 1. Over weeks of treatment this shift is associated with a selective decrease in fat stored inside the abdomen.